1. Ems D, Murty S, Loy B, Gallagher J, Happe LE, Rogstad TL, Fennel D, Fernandez J. Alternative payment models in medical oncology: Outcomes under partial capitation. Am Health Drug Benefits. 2018.  2018;7(11):371-378.

  2. Lee AN, Johnson R, Lakhani, Happe LE. Outcomes at bariatric surgery centers of excellence and non-designated centers: A retrospective cohort study in a TRICARE population. Am Surg. 2018;84(3):410-415.

  3. Espinosa CM, Marshall GS, Woods CR, Ma Q, Ems D, Nsiah I, Happe LE, Smith MJ. Missed opportunities for human papillomavirus vaccine initiation in an insured adolescent female population. J Pediatric Infect Dis Soc. 2017;6(4):360-5.

  4. Powell AC, Mirhadi AJ, Loy BA, Happe LE, Long JW, Kren EM, Gupta AK. Presentation at computed tomography scan of the thorax and first year diagnostic and treatment utilization among patients diagnosed with lung cancer. PLoS One. 2017 Jul 14;12(7):e0181319. doi: 10.1371/journal.pone.0181319. eCollection 2017.

  5. Beech BM, Cordier T, Happe LE, Trunk L, Haugh GS, Kwong R, Gopal V, Beveridge RA. Does a free office visit affect primary care-seeking behavior? A study of new exchange health plan enrollees in Mississippi. Am Health Drug Benefits. 2017;10(2):64-71.

  6. Castro Sweet CM, Chiguluri V, Gumpina R, Abbott P, Madero EN, Payne M, Happe L, Matanich R, Renda A, Prewitt T. Outcomes of a digital health program with human coaching for diabetes risk reduction in a Medicare population. J Aging Health. 2017; January 24. [Epub ahead of print]

  7. Robertson-Cooper H, Neaderhiser B, Happe LE, Beveridge RA. Family physician readiness for value-based payments: Does ownership status matter? Popl Health Manag. 2017 Oct;20(5):357-361. doi: 10.1089/pop.2016.0135. Epub 2017 Jan 18.

  8. Slabaugh L, Shah M, Zack M, Happe L, Cordier T, Havens E, Davidson E, Miao M, Prewitt T, Jia H. Leveraging health related quality of life in population health management: The case for Healthy Days. Popul Health Manag. 2017;20(1):13-22.

  9. Beveridge RA, Happe LE, Funk M. The physician-insurer dynamic must shift to successfully implement value-based payments. Healthc(Amst). 2016;4(4):282-284.

  10. Loy B, Shkedy C, Powell A, Happe L, Royalty J, Miao M, Smith G, Long J, Gupta A.  Do case rates affect physicians’ clinical practice in radiation oncology? PLoS One. 2016;11(2):e0149449.

  11. Lopez A, Long CL, Happe LE, Relish M. Using sequence discovery to target outreach for diabetes medication adherence. Am J Manag Care. 2015;21(11):e601-e608.

  12. Ward MA, Fang G, Richards KL, Walko CM, Earnshaw SR, Happe LE, Blalock SJ. Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization , and healthcare costs. Curr Med Res Opin. 2015;31(2):289-97.

  13. Franklin MA, Happe LE, Dillman R, Marshall LZ. Frequency and economic impact of comorbid cardiac conditions with multiple sclerosis.  J Manag Care Spec Pharm. 2014;20(8):795-9.

  14. Happe LE, Holliday E, Young T, Clark D. A systematic literature review of the directional impact of managed care formulary restrictions on patient outcomes. J Manag Care Pharm. 2014;20(7):677-84.

  15. Happe LE.  Choosing the best treatment for multiple sclerosis: Comparative effectiveness, safety, and other factors involved in disease modifying therapy choice. Am J Manag Care. 2013;19:S332-S342.

  16. Happe LE, Walker D. Pharmacy Students for an Evolving Health Care Delivery System Through the Use of Grey Literature. Am J Pharm Educ. 2013;44(7):1-7.

  17. Miller R, Happe LE, Meyer K, Spear R. Approaches to the management of agents used for the treatment of multiple sclerosis: Consensus statements from a panel of United States managed care pharmacists and physicians. J Manag Care Pharm. 2012;18(1):54-62.

  18. Farias-Eisner R, Horblyuk R, Franklin M, Lunacsek O, Happe L. Economic and clinical evaluation of fondaparinux vs. enoxaparin for thromboprophylaxis following general surgery.  CMRO.  2009;25(5):1081-1087.

  19. Happe LE, Rao SV, Horblyuk R, Franklin M, Lunacsek OE, Menditto L.  Consequences of major bleeding in hospitalized patients with non-ST segment elevation acute coronary syndromes receiving injectable anticoagulants.  CMRO.  2009;25(2):413-420.

  20. Happe LE, Lunacsek OE, Kruzikas DT, Marshall GS.  Impact of a pentavalent combination vaccine on immunization timeliness in a state Medicaid population.  Pediatr Infect Dis J. 2009;28(2):98-101.

  21. Shorr AF, Nutescu E, Farrelly E, Horblyuk R, Happe L, Franklin M.  Postdischarge oral versus injectable anticoagulation following major orthopedic surgery. Ann Pharmacother.  2008;42:1216-1221.

  22. Nutescu E, Shorr AF, Farrelly E, Horblyuk R, Happe L, Franklin M.  Burden of Deep Vein Thrombosis in the Outpatient Setting Following Major Orthopedic Surgery.  Ann Pharmacother.  2008;42:1222-1228.

  23. Kwong LM, Happe LE, Horblyuk R, Farrelly E.  Decreased venous thromboembolism with injectable vs oral anticoagulation following discharge for major orthopaedic surgery. J Arthroplasty. 2008 Sep;23(6 Suppl 1):25-30.

  24. Comp P, Happe LE, Sarnes MW, Farrelly E.  Clinically-Detected Venous Thromboembolism Following Hip Fracture Surgery with Prophylaxis in a Clinical Practice Setting.  Am Journal Orthop.  2008;37(9)470-475.

  25. Shorr A, Sarnes M, Peeples P, Stanford R, Happe L, Farrelly E.  Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery.  Am J Health Syst Pharm. 2007 Nov 15;64(22):2349-55.

  26. Shorr A, Kwong L, Sarnes M, Happe L, Farrelly E, Mody-Patel N.  Venous thromboembolism after orthopedic surgery: Implications of the choice for prophylaxis.  Thromb Res.  2007. 121(1): 17-24.

  27. Happe L, Farrelly E, Stanford RH, Sarnes M.  Cost and occurrence of thrombocytopenia in patients receiving venous thromboembolism prophylaxis following orthopaedic surgeries.  Journal of Thrombosis and Thrombolysis.  2008;26(2):125-31.

  28. Marshall GS, Happe LE, Lunacsek OE, Szymanski MD, Woods CR, Russell AR.  Use of combination vaccines is associated with improved coverage rates.  Pediatr Infect Dis J 2007;26: 496–500.

  29. Happe LE, Lunacsek OE, Marshall GS, Lewis T, Spencer S.  Combination vaccine use and vaccination quality in a managed care population.  Am J Manag Care.  2007;13:506-512.

  30. Eaddy MT, Druss BG, Sarnes MW, Regan TS, Frankum (Happe) LE.  Relationship of total health care charges to selective serotonin reuptake inhibitor utilization patterns including the length of antidepressant therapy--results from a managed care administrative claims database. J Manag Care Pharm. 2005;11(2):145-150.

  31. Frankum (Happe) LE, Nightengale B, Russo CL, Sarnes MW.  Pharmacoeconomic analysis of sequential treatment pathways in the treatment of onychomycosis. Manag Care Interface. 2005;18(1):55-63.

  32. Sarnes MW, Frankum (Happe) LE. Pharmacoeconomic evaluation of antidepressant therapies. Manag Care. 2004;13(suppl 6):34-41.


American Drug and Health Benefits

American Journal of Managed Care

Am J of Pharmaceutical Education

Annals of Pharmacotherapy

J Managed Care & Specialty Pharmacy

J Pediatric Infectious Disease Society

Population Health Management


Centers for Disease Control

Harvard University

Robert Wood Johnson Foundation

University of Florida

University of Kentucky

University of Louisville

University of Maryland

University of Mississippi

University of Pennsylvania

University of Texas at Austin